← Leaderboards
Mary A Staat
Children'S Hospital Med Ctr (Cincinnati)
$67,374,420
Attributed
$67,374,420
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $9.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,362,169 · 1
CDC$31,012,251 · 5
By mechanism
U01$66,472,729 · 5
U38$901,691 · 1
Top collaborators
No co-investigators on record.
Most similar at Children'S Hospital Med Ctr (Cincinnati)
Same institution · by research overlap
- Carl J Fichtenbaum$10,319,458
- Ardythe L. Morrow$9,798,109
Others in their field
Top investigators on “Postnatal”
- Leonardo Trasande · New York University School Of Medicine$79,321,500
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Rosalind J Wright · Icahn School Of Medicine At Mount Sinai$39,079,074
- Nenad Sestan · Yale University$36,892,570
- Robert O Wright · Brigham And Women'S Hospital$30,687,606
- Corette B Parker · Research Triangle Institute$29,747,495
Research focus
PostnatalAntibodiesRecruitPregnant WomenSymptomsVirusInfectionInfantLifePredispositionImmune ResponseSamplingChildImmuneImmunityCohortCollectionImmunologicsInfluenzaInfrastructureMothersElderlyChildhoodGenetic Programming
Grant awards (41)
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$3,381,331
U01 · FY2025 · AI · contact PI
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$1,996,220
U01 · FY2025 · IP · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,237,040
U01 · FY2024 · AI · contact PI
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$1,234,285
U01 · FY2024 · IP · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,346,579
U01 · FY2023 · AI · contact PI
IP21-002 US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$2,749,997
U01 · FY2023 · IP · contact PI
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$2,300,000
U01 · FY2023 · IP · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,442,677
U01 · FY2022 · AI · contact PI
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$1,935,998
U01 · FY2022 · IP · contact PI
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children$816,161
U01 · FY2022 · AI · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,441,694
U01 · FY2021 · AI · contact PI
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children$3,123,720
U01 · FY2021 · AI · contact PI
US Enhanced Surveillance Network to Assess Burden, Natural History, and Effectiveness of Vaccines to Prevent Enteric and Respiratory Viruses in Children$1,441,646
U01 · FY2021 · IP · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,386,974
U01 · FY2020 · AI · contact PI
COVID-19 Epidemiology and Immune-Pathogenesis in Pregnant Women, Mothers and Children$2,530,068
U01 · FY2020 · AI · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$2,193,828
U01 · FY2020 · IP · contact PI
Impact of the Initial Influenza Exposure on the Quality, Magnitude, Breadth, Potency and Durability of Influenza Immunity$4,655,925
U01 · FY2019 · AI · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$2,450,000
U01 · FY2019 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$562,720
U01 · FY2019 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$2,426,950
U01 · FY2018 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$250,000
U01 · FY2018 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$2,200,000
U01 · FY2017 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$1,985,712
U01 · FY2016 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$214,285
U01 · FY2016 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$566,930
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$385,714
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$214,285
U01 · FY2015 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$391,529
U01 · FY2014 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$191,291
U01 · FY2014 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$391,529
U01 · FY2013 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$158,471
U01 · FY2013 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$295,800
U01 · FY2012 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$214,152
U01 · FY2012 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease$348,780
U01 · FY2011 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Disease -Patient Protection-ACA$201,220
U01 · FY2011 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$579,324
U01 · FY2010 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$488,496
U01 · FY2009 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$954,794
U01 · FY2008 · IP · contact PI
Enhanced Surveillance for New Vaccine Preventable Diseases$786,604
U01 · FY2007 · IP · contact PI
Enhanced surveillance for newly vaccine preventable disease$901,691
U38 · FY2006 · IP · contact PI
Enhanced surveillance for newly vaccine preventable disease$0
U38 · FY2005 · IP